ReNerve Limited (ASX: RNV) - Share Price

- Current share price for RNV : $0.077

ReNerve Limited (RNV) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian biotechnology company that has altered peripheral nerve surgery with its ready-to-use solutions for peripheral nerve injuries (PNI).

RNV General Information ⁺

ASX Code	RNV
Website	http://www.renerve.com.au
Industry/Sector	Health Care Supplies
Market Cap ($M)	10
RNV Share Price	$0.077
Day High	$0.000
Day Low	$0.000
Last Close	$0.077
RNV Share Price Movement	- ( No change )

Prices as at 16:40, 16 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

ReNerve Limited (RNV) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from ReNerve Limited (RNV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ReNerve Limited (RNV) price-sensitive announcements

RNV - Positive FDA Feedback on NervAlign Nerve Guide Matrix

ReNerve Limited announced that it received positive feedback from the US Food and Drug Adm

ReNerve Limited (RNV)
14 Oct 2026 | 9:28 AM

RNV - ReNerve AGM Presentation

ReNerve Limited’s AGM presentation for October 2026 outlines the company’s strategy to bui

ReNerve Limited (RNV)
5 Oct 2026 | 1:20 PM

RNV - ReNerve completes first cases in Hong Kong and Malaysia

ReNerve Limited (ASX: RNV) announced that it has completed the first commercial surgical c

ReNerve Limited (RNV)
21 Sep 2026 | 9:08 AM

RNV - ReNerve and RMIT awarded $499k grant

ReNerve Limited announced that, together with RMIT and Associate Professor Shadi Houshyar,

ReNerve Limited (RNV)
7 Sep 2026 | 9:22 AM

ReNerve Limited (RNV) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Positive FDA Feedback on NervAlign Nerve Guide Matrix	14 Oct 2026 9:28AM	$0.080	$0.077	fallen by 3.75%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Change of Director's Interest Notice - P Savage	6 Oct 2026 1:34PM	$0.080	$0.077	fallen by 3.75%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Change of Director's Interest Notice - M McGuire	6 Oct 2026 1:34PM	$0.080	$0.077	fallen by 3.75%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Change of Director's Interest Notice - J Chick	6 Oct 2026 1:33PM	$0.080	$0.077	fallen by 3.75%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Cleansing Notice	6 Oct 2026 1:18PM	$0.080	$0.077	fallen by 3.75%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Application for quotation of securities - RNV	6 Oct 2026 1:14PM	$0.080	$0.077	fallen by 3.75%

RNV Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$5.57	-$3.50	15.50%	0.00%	0.0%
2025A	-$3.73	-$3.00	44.30%	0.00%	0.0%
2024A	-$2.98	-$2.10	65.40%	0.00%	0.0%

RNV Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Ansell Limited (ANN)	$6,408M	0.1231	-0.0819	0.1002	21.2537	23.1498	21.0412	2.17%	1.82%	2.02%
Nanosonics Limited (NAN)	$838M	-0.1375	-0.3501	0.6933	48.5269	74.6667	44.0945	0.00%	0.00%	0.00%
Polynovo Limited (PNV)	$618M	-0.0899	-0.4186	1.0000	52.0349	89.5000	44.7500	0.00%	0.00%	0.00%
ReNerve Limited (RNV)	$11M	0.1551	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

RNV Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	4.18	0.00
Market	0.31	13.60	1.05	0.72
Sector	0.74	21.70	1.88	2.49

RNV Directors

Name	Position	Start Date
Dr Julian John Chick	Chief Executive Officer, Executive Director	16 Sep 2016
Ms Maja Aleksandra McGuire	Interim Chairman, Non-Executive Director	4 Dec 2025
Mr Paul Savage	Non-Executive Director	4 Dec 2025

ReNerve Limited (RNV) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
11 Sep 2026	CHICK, Julian	Buy	Indirect Shares	128,036	$0.075	$9,641.111
31 Jul 2026	CHICK, Julian	Buy	Direct Shares	292,565	$0.083	$24,341.408
31 Jul 2026	CHICK, Julian	Buy	Indirect Shares	292,565	$0.083	$24,341.408

See all changes in directors' interest & trades for ReNerve Limited (RNV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RNV Management

Name	Position
David Lilja	Chief Financial Officer,Company Secretary

RNV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ReNerve Limited (RNV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
12,458,090 (7.23%)	Ropehawn Investments Pty Ltd
11,527,500 (6.69%)	Lucen Pty Ltd
10,170,788 (5.90%)	Zetland Road Pty Ltd

RNV Calendar of Events

Date	Event
27 August 2027	Report (Annual)
27 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us